Author(s): Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS,
Abstract Share this page
Abstract Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3\%) of ≥3 darunavir resistance-associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.
This article was published in AIDS Res Hum Retroviruses
and referenced in Journal of Antivirals & Antiretrovirals